These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 23619157)

  • 1. Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.
    Eder L; Thavaneswaran A; Chandran V; Gladman DD
    Ann Rheum Dis; 2014 Jun; 73(6):1007-11. PubMed ID: 23619157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors.
    Finzel S; Kraus S; Schmidt S; Hueber A; Rech J; Engelke K; Englbrecht M; Schett G
    Ann Rheum Dis; 2013 Jul; 72(7):1176-81. PubMed ID: 22915620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods.
    Eder L; Chandran V; Gladman DD
    J Rheumatol; 2011 Jun; 38(6):1066-70. PubMed ID: 21324963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.
    Kavanaugh A; Ritchlin C; Rahman P; Puig L; Gottlieb AB; Li S; Wang Y; Noonan L; Brodmerkel C; Song M; Mendelsohn AM; McInnes IB;
    Ann Rheum Dis; 2014 Jun; 73(6):1000-6. PubMed ID: 24553909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
    Smolen JS; van der Heijde DM; Aletaha D; Xu S; Han J; Baker D; St Clair EW
    Ann Rheum Dis; 2009 Oct; 68(10):1535-40. PubMed ID: 18957487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
    Ikeda K; Nakagomi D; Sanayama Y; Yamagata M; Okubo A; Iwamoto T; Kawashima H; Takahashi K; Nakajima H
    J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
    Zisapel M; Zisman D; Madar-Balakirski N; Arad U; Padova H; Matz H; Maman-Sarvagyl H; Kaufman I; Paran D; Feld J; Litinsky I; Wigler I; Caspi D; Elkayam O
    J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
    Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Noonan L; Hsia EC
    J Rheumatol; 2019 Jun; 46(6):595-602. PubMed ID: 30770519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.
    Di Minno MN; Peluso R; Iervolino S; Russolillo A; Lupoli R; Scarpa R;
    Ann Rheum Dis; 2014 Jun; 73(6):1157-62. PubMed ID: 23771989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History.
    Jadon DR; Shaddick G; Tillett W; Korendowych E; Robinson G; Waldron N; Cavill C; McHugh NJ
    J Rheumatol; 2015 Jul; 42(7):1169-76. PubMed ID: 25979723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
    Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Koldingsnes W; Mowinckel P; Kvien TK
    Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers.
    Di Minno MN; Iervolino S; Peluso R; Russolillo A; Lupoli R; Scarpa R; Di Minno G; Tarantino G;
    J Rheumatol; 2012 May; 39(5):1042-6. PubMed ID: 22422493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis.
    Chandran V; Shen H; Pollock RA; Pellett FJ; Carty A; Cook RJ; Gladman DD
    J Rheumatol; 2013 Jun; 40(6):866-71. PubMed ID: 23637322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab.
    Klarenbeek NB; Güler-Yüksel M; van der Heijde DM; Hulsmans HM; Kerstens PJ; Molenaar TH; de Sonnaville PB; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2010 Dec; 69(12):2107-13. PubMed ID: 20610442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.